| Filed |
Name |
|
Company |
Pur. £ |
Cur. £ |
P/L % |
MPV* |
|
Apr '12
|
Lord Glendonbrook
|
|
Astrazeneca / LSE:AZN.L |
£2,666.50
|
£14,492.00
|
443.48%
|
£380,438.78
|
|
Apr '10
|
Baroness Noakes
|
|
Astrazeneca / LSE:AZN.L |
£2,938.00
|
£14,492.00
|
393.26%
|
£345,282.51
|
|
Mar '14
|
Viscount Eccles
|
|
Astrazeneca / LSE:AZN.L |
£3,876.50
|
£15,316.00
|
295.10%
|
£276,569.07**
|
|
Feb '11
|
Lord Wasserman
|
|
Johnson & Johnson / NYQ:JNJ |
£60.93
|
£230.65
|
278.55%
|
£264,984.40
|
|
Dec '16
|
Lord Burns
|
|
Astrazeneca / LSE:AZN.L |
£4,116.00
|
£14,492.00
|
252.09%
|
£246,462.59
|
|
Jan '13
|
Lord Sassoon
|
|
Johnson & Johnson / NYQ:JNJ |
£72.69
|
£230.65
|
217.31%
|
£222,114.45
|
|
May '11
|
Lord Glendonbrook
|
|
Novartis / NYQ:NVS |
£54.04
|
£147.48
|
172.90%
|
£191,031.96
|
|
May '18
|
Lord Grabiner
|
|
Astrazeneca / LSE:AZN.L |
£5,417.00
|
£14,492.00
|
167.53%
|
£187,269.71
|
|
Apr '17
|
Lord Donoughue
|
|
Novartis / NYQ:NVS |
£66.05
|
£147.48
|
123.29%
|
£156,303.59
|
|
Sep '16
|
Lord Gadhia
|
|
Astrazeneca / LSE:AZN.L |
£5,099.00
|
£10,024.00
|
96.59%
|
£137,611.30**
|
|
Feb '21
|
Lord Etherton
|
|
Astrazeneca / LSE:AZN.L |
£7,422.00
|
£14,492.00
|
95.26%
|
£136,680.14
|
|
Jul '16
|
Lord Lloyd-Webber
|
|
Johnson & Johnson / NYQ:JNJ |
£122.64
|
£230.65
|
88.07%
|
£131,649.54
|
|
Jun '21
|
Lord Morse
|
|
Astrazeneca / LSE:AZN.L |
£8,005.00
|
£14,492.00
|
81.04%
|
£126,725.80
|
|
Apr '21
|
Baroness Deech
|
|
Novartis / NYQ:NVS |
£88.38
|
£147.48
|
66.87%
|
£116,809.23
|
|
Aug '14
|
Lord Carter of Coles
|
|
Johnson & Johnson / NYQ:JNJ |
£100.16
|
£161.55
|
61.29%
|
£112,904.35**
|
|
May '25
|
Lord Hayward
|
|
Glaxosmithkline / NYQ:GSK |
£37.37
|
£55.63
|
48.86%
|
£104,203.91
|
|
Dec '16
|
Lord Burns
|
|
Glaxosmithkline / NYQ:GSK |
£37.39
|
£55.63
|
48.78%
|
£104,148.17
|
|
Mar '25
|
Lord Fink
|
|
Johnson & Johnson / NYQ:JNJ |
£161.72
|
£230.65
|
42.62%
|
£99,836.13
|
|
Nov '23
|
Lord Mance
|
|
Astrazeneca / LSE:AZN.L |
£10,230.00
|
£14,492.00
|
41.66%
|
£99,163.25
|
|
Apr '10
|
Lord Levene of Portsoken
|
|
Glaxosmithkline / NYQ:GSK |
£39.38
|
£55.63
|
41.26%
|
£98,885.22
|
|
Nov '23
|
Lord Mance
|
|
Eli Lilly Co / VIE:LLYC.VI |
£557.00
|
£785.60
|
41.04%
|
£98,728.90
|
|
Apr '10
|
Baroness Noakes
|
|
Glaxosmithkline / NYQ:GSK |
£39.49
|
£55.63
|
40.87%
|
£98,609.77
|
|
May '23
|
Lord Fink
|
|
Johnson & Johnson / NYQ:JNJ |
£165.03
|
£230.65
|
39.76%
|
£97,833.73
|
|
May '11
|
Lord Glendonbrook
|
|
Pfizer / NYQ:PFE |
£19.54
|
£26.67
|
36.46%
|
£95,520.03
|
|
May '20
|
Lord Deighton
|
|
Astrazeneca / LSE:AZN.L |
£8,361.00
|
£11,236.00
|
34.39%
|
£94,070.09**
|
|
Mar '17
|
Lord Lloyd-Webber
|
|
Glaxosmithkline / NYQ:GSK |
£42.31
|
£55.63
|
31.48%
|
£92,037.34
|
|
May '11
|
Lord Glendonbrook
|
|
Glaxosmithkline / NYQ:GSK |
£42.78
|
£55.63
|
30.04%
|
£91,026.18
|
|
Jan '24
|
Lord Fink
|
|
Roche / EBS:ROG.SW |
£251.85
|
£324.90
|
29.01%
|
£90,303.75
|
|
Apr '17
|
Lord Leigh of Hurley
|
|
Roche / EBS:ROG.SW |
£255.80
|
£324.90
|
27.01%
|
£88,909.30
|
|
May '24
|
Lord Balfe
|
|
Glaxosmithkline / NYQ:GSK |
£44.02
|
£55.63
|
26.37%
|
£88,462.06
|
|
Apr '24
|
Lord Mendoza
|
|
Eli Lilly / NYQ:LLY |
£731.33
|
£917.65
|
25.48%
|
£87,833.81
|
|
May '24
|
Lord Goldsmith
|
|
Abbvie / NYQ:ABBV |
£160.81
|
£200.95
|
24.96%
|
£87,472.79
|
|
Jan '13
|
Lord Sassoon
|
|
Glaxosmithkline / NYQ:GSK |
£44.75
|
£55.63
|
24.31%
|
£87,019.00
|
|
May '23
|
Lord Fink
|
|
Astrazeneca / LSE:AZN.L |
£11,774.00
|
£14,492.00
|
23.08%
|
£86,159.33
|
|
May '23
|
Lord Londesborough
|
|
Astrazeneca / LSE:AZN.L |
£11,924.00
|
£14,492.00
|
21.54%
|
£85,075.48
|
|
Apr '24
|
Lord Balfe
|
|
Astrazeneca / LSE:AZN.L |
£12,024.00
|
£14,492.00
|
20.53%
|
£84,367.93
|
|
May '24
|
Lord Goldsmith
|
|
Astrazeneca / LSE:AZN.L |
£12,156.00
|
£14,492.00
|
19.22%
|
£83,451.79
|
|
Aug '17
|
Lord Sterling of Plaistow
|
|
Johnson & Johnson / NYQ:JNJ |
£133.45
|
£157.98
|
18.38%
|
£82,866.99**
|
|
Apr '23
|
Lord Grabiner
|
|
Novartis / NYQ:NVS |
£95.80
|
£107.52
|
12.23%
|
£78,563.67**
|
|
Apr '21
|
Lord Farmer
|
|
Glaxosmithkline / NYQ:GSK |
£36.65
|
£40.88
|
11.54%
|
£78,079.12**
|
|
Oct '20
|
Lord Taverne
|
|
Glaxosmithkline / NYQ:GSK |
£37.57
|
£40.95
|
9.00%
|
£76,297.58**
|
|
Mar '25
|
Lord Fink
|
|
Roche / EBS:ROG.SW |
£303.00
|
£324.90
|
7.23%
|
£75,059.40
|
|
Mar '14
|
Baroness Eccles of Moulton
|
|
Glaxosmithkline / NYQ:GSK |
£53.43
|
£56.69
|
6.10%
|
£74,271.01**
|
|
Nov '25
|
Lord Green of Hurstpierpoint
|
|
Roche / EBS:ROG.SW |
£309.00
|
£324.90
|
5.15%
|
£73,601.94
|
|
Apr '21
|
Lord Grabiner
|
|
Roche / EBS:ROG.SW |
£309.65
|
£324.90
|
4.92%
|
£73,447.44
|
|
May '23
|
Lord Leitch
|
|
Astrazeneca / LSE:AZN.L |
£11,820.00
|
£12,340.00
|
4.40%
|
£73,079.53**
|
|
Apr '26
|
Lord Grabiner
|
|
Eli Lilly / NYQ:LLY |
£955.19
|
£917.65
|
-3.93%
|
£67,248.93
|
|
Feb '25
|
Lord Green of Hurstpierpoint
|
|
Roche / EBS:ROG.SW |
£285.70
|
£272.40
|
-4.66%
|
£66,741.33**
|
|
Feb '16
|
Lord Lloyd-Webber
|
|
Pfizer / NYQ:PFE |
£29.02
|
£26.67
|
-8.11%
|
£64,325.36
|
|
Jan '20
|
Lord Gadhia
|
|
Glaxosmithkline / NYQ:GSK |
£46.50
|
£40.95
|
-11.94%
|
£61,645.16**
|
|
Apr '22
|
Lord Cromwell
|
|
Johnson & Johnson / NYQ:JNJ |
£179.90
|
£154.37
|
-14.19%
|
£60,066.15**
|
|
May '23
|
Lord Reay
|
|
Sanofi / NMS:SNY |
£55.11
|
£47.22
|
-14.32%
|
£59,978.23**
|
|
Aug '16
|
Lord Lloyd-Webber
|
|
Eli Lilly / NYQ:LLY |
£80.55
|
£67.15
|
-16.64%
|
£58,355.06**
|
|
Aug '20
|
Lord Reay
|
|
Roche / EBS:ROG.SW |
£315.05
|
£249.80
|
-20.71%
|
£55,502.30**
|
|
Jul '18
|
Lord Glendonbrook
|
|
Bayer / GER:BAYN.DE |
£95.26
|
£40.04
|
-57.97%
|
£29,422.63
|
* Minimum Potential Value based on £70,000.00 invested at time of declaration.
** Interest ceased/exited on filed date.